Poland· PL-100467982
Skytrofa
A lonapegsomatropin product containing lonapegsomatropinum, registered in Poland by Ascendis Pharma Endocrinology Division A/S. The same ATC class is registered in 8 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Lonapegsomatropin is registered in 8 of 19 countries.
Countries holding a registration under ATC H01AC09 (lonapegsomatropin), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 5 of them publish a price we can compare per daily dose
Lonapegsomatropin · ATC H01AC09
8 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Ireland
- Netherlands
- Polandprice
- United Statesprice
The record
At a glance
URPL (Poland)- Active substance
- Lonapegsomatropinum
- Manufacturer
- Ascendis Pharma Endocrinology Division A/S
- Country
- Poland (PL)
- ATC code
- H01AC09
- ATC class
- Lonapegsomatropin
- Defined daily dose
- 0.9 mg, P
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Lonapegsomatropin in 5 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumSkytrofa 4.3 mgAscendis Pharma Endocrinology Division
- SwedenSkytrofa 4,3 mg Pulver och vätska till injektionsvätska, lösning i cylinderampullAscendis Pharma Endocrinology Division A/S
- United StatesSkytrofaAscendis Pharma Endocrinology, Inc.
- FinlandSkytrofaAscendis Pharma Endocrinology Division A/S
- NetherlandsSkytrofa 11 mg, poeder en oplosmiddel voor oplossing voor injectie in een patroonAscendis Pharma Endocrinology Division A/S
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Skytrofa
- Liechtenstein · Skytrofa
- Norway · Skytrofa
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/94b47ef1-41e6-426d-81f2-eccd36e17c83 GET /v1/drugs/94b47ef1-41e6-426d-81f2-eccd36e17c83?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Proszek i rozpuszczalnik do sporządzania roztworu do wstrzykiwań",
"source": "urpl",
"strength": "4,3 mg",
"packaging": "Rpz ¦ EU/1/21/1607/003 ¦ 144837\n4 wkłady 4,3 mg + 0,388 ml rozp. ¦ 6 igieł",
"substance": "Lonapegsomatropinum 4.3 mg",
"common_name": "Lonapegsomatropinum",
"pl_product_id": "100467982",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about lonapegsomatropin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.